NexDx, Inc., a San Diego, CA-based biotech company, has closed a $2.1m Series B financing.
The company intends to use the funding to support ongoing research and development and progress its lead molecular diagnostic test for rheumatoid arthritis into analytical and clinical validation.
founded in August 2011 by Chairman and CEO Jonathan E. Lim, M.D. and Gary S. Firestein, M.D. (Professor of Medicine at UC San Diego), NexDx is a science driven molecular diagnostics company providing next generation products and services for personalized medicine in rheumatoid arthritis and other autoimmune diseases.